About Aramchol™
Aramchol™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate. Aramchol™ is a first in class, orally active, liver targeted SCD – 1 modulator with a dual mode of action on liver fibrosis, down regulation of steatosis and a direct effect on Hepatic Stellate Cells (HSC’s), the human collagen producing cells. Aramchol™ has shown down regulation of liver steatosis and fibrosis in multiple animal models (see also publication section) demonstrating its effect on the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol™ on NASH pathologies in animals was translated into humans in a phase IIa clinical study and is currently being examined in the Phase IIb ARREST study (see also Clinical Development section). To date, over 400 patients have been exposed to Aramchol™ across 7 clinical trials. No safety and tolerability signals have been identified thus far. Aramchol™ has been granted Fast Track designation status by the FDA for the treatment of NASH.
First‐in‐class, orally active, liver targeted SCD‐1 modulator
Potent mechanism with multiple intervention points along the pathogenic pathway
Effects in animal models into human ctranslated linical data
High safety margin and B/R ratio
~400 subjects exposed across 7 clinical trials
Fast Track Designation for development of Aramchol™ for NASH granted by FDA
